Monte Rosa Therapeutics (Monte Rosa Therapeutics) Growth Rank : 0 (As of May. 31, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Monte Rosa Therapeutics Growth Rank?

Monte Rosa Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Monte Rosa Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Monte Rosa Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monte Rosa Therapeutics Inc (NAS:GLUE) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 102, Boston, MA, USA, 02210

Website

https://www.monterosatx.com

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.

Executives

Edmund Dunn	officer: Principal Accounting Officer	MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210
Anthony M. Manning	director	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jan Skvarka	director	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Philip Nickson	officer: General Counsel	MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Julian G Jones	officer: Chief Business Officer	MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
New Enterprise Associates 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093